Cochrane · systematic review · CD013414
Metformin for preventing the progression of chronic kidney disease
El-Damanawi, R, Stanley, IK, Staatz, C, et al. · Cochrane Database of Systematic Reviews · 2024 · Cochrane Library
Kidney and TransplantAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
13
No studies
1
Included studies
NR
No studies 1 · 7.1%Ungraded 0 · 0%Very low 4 · 28.6%Low 3 · 21.4%Moderate 6 · 42.9%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Metformin versus placebo for preventing the progression of chronic kidney disease
Population: preventing the progression of CKD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
eGFR: change ( Metformin vs placebo | no estimate extracted | 3 studies · 505 participants | Low Downgraded: indirectness |
All‐cause death ( Metformin vs placebo | RR 1 [0.76, 1.32] | 3 studies · 865 participants | Very low Downgraded: indirectness |
Serious adverse events ( Metformin vs placebo | RR 1.15 [0.76, 1.72] | 3 studies · 576 participants | Moderate Downgraded: indirectness |
Withdrew due to intolerance ( Metformin vs placebo | RR 2.19 [1.46, 3.27] | 4 studies · 646 participants | Moderate Downgraded: imprecision, indirectness |
Dose tolerability ( Metformin vs placebo | no estimate extracted | 3 studies · 576 participants | Moderate Downgraded: indirectness |
Kidney failure (median Metformin vs placebo | RR 1.2 [0.17, 8.49] | 1 study · 753 participants | Very low Downgraded: indirectness |
Change in proteinuria (1 year) Metformin vs placebo | no estimate extracted | 2 studies · 100 participants | Very low Downgraded: indirectness |
Metformin versus active control for preventing the progression of chronic kidney disease
Population: preventing the progression of CKD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
eGFR: change (4 years) Metformin vs active control | no estimate extracted | 1 study · 3914 participants | Very low Downgraded: indirectness |
All‐cause death ( Metformin vs active control | RR 0.95 [0.63, 1.43] | 3 studies · 5608 participants | Low Downgraded: indirectness |
Serious adverse events ( Metformin vs active control | RR 1.16 [0.79, 1.71] | 2 studies · 5545 participants | Moderate Downgraded: imprecision, inconsistency, indirectness |
Withdrew due to intolerance ( Metformin vs active control | RR 0.92 [0.79, 1.08] | 3 studies · 5593 participants | Moderate Downgraded: imprecision, inconsistency, indirectness |
Dosing and tolerance ( Metformin vs active control | no estimate extracted | 3 studies · 3 participants | Moderate Downgraded: imprecision, inconsistency, indirectness |
Kidney failure Metformin vs active control | no estimate extracted | NR | No studies |
UACR (% change) ( Metformin vs active control | no estimate extracted | 2 studies · 3836 participants | Low Downgraded: indirectness |